Skip to main content
Premium Trial:

Request an Annual Quote

Waters Licenses Mass Spec Standardization Tech From SISCAPA

NEW YORK (GenomeWeb) – SISCAPA Assay Technologies (SAT) said Wednesday that it has licensed a stable isotope-labeled (SIL) standards technology to Waters.

Waters said it will use the non-exclusive license to explore the technology as a tool for standardizing quantitative mass spec assays.

The technology uses multiple SIL standards to target molecules, allowing researchers to create internal standard calibration curves for their assays. According to SAT, this could lower the time and cost of such assays.

“With the licensing of SAT’s technology, we are now in the process of evaluating the benefits of the approach for quantitative LC/MS assays in a number of application areas,” Jeff Mazzeo, Waters vice president of marketing, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.